Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
7(64%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
27%
Ph phase_2
2
18%
Ph early_phase_1
1
9%
Ph phase_1
2
18%
Ph phase_4
1
9%

Phase Distribution

3

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(3)

Detailed Status

Recruiting6
Completed3
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (11.1%)
Phase 12 (22.2%)
Phase 22 (22.2%)
Phase 33 (33.3%)
Phase 41 (11.1%)

Trials by Status

completed327%
not_yet_recruiting19%
recruiting655%
active_not_recruiting19%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_2

Pan Tumor Rollover Study

NCT03899155
recruitingphase_2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
recruitingphase_3

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180
recruitingphase_1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

NCT05176483
recruitingphase_1

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

NCT04697576
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03899155Phase 2

Pan Tumor Rollover Study

Recruiting
NCT06295159Phase 2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting
NCT06264180Phase 3

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Recruiting
NCT05176483Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Recruiting
NCT04697576Phase 1

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Recruiting
NCT07459543Phase 4

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Not Yet Recruiting
NCT06112314Phase 3

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Recruiting
NCT07091695

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Completed
NCT05704933Early Phase 1

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Completed
NCT05625399Phase 3

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Active Not Recruiting
NCT07079644

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11